Observational studyAlimentary pharmacology & therapeutics2020
A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease.
Observational study in Alimentary pharmacology & therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Second United Arab Emirates consensus guidance on the diagnosis and management of inflammatory bowel disease.World journal of gastroenterology · 2025Pooled it
- Clinical decision support for potentially sedating drugs in palliative care: a mixed-methods pilot study.BMC palliative care · 2026Article
- Predictive Utility of the Vedolizumab Clinical Decision Support Tool in a Real-World IBD Cohort: Differential Performance in Crohn's Disease and Ulcerative Colitis.Medicina (Kaunas, Lithuania) · 2026Article
- Recent Advances in Molecular Targeted Therapy for Inflammatory Bowel Disease.Internal medicine (Tokyo, Japan) · 2026Review
- A decade of clinical data with vedolizumab: the past, present, and future.Therapeutic advances in gastroenterology · 2026Review
- Vedolizumab clinical decision support tool predicts clinically relevant targets in patients with Crohn's disease.Therapeutic advances in gastroenterology · 2026Article
- Development and Validation of a Clinical Decision Support Tool to Predict Disease Progression in Crohn's Disease Treated with Ustekinumab.Journal of clinical medicine · 2025Article
- A Guide to the Patient-Centric Use of Vedolizumab for Crohn's Disease.Inflammatory bowel diseases · 2025Review
- Artificial Intelligence in Advancing Inflammatory Bowel Disease Management: Setting New Standards.Cancers · 2025Review
- Real-World Effectiveness and Patient Stratification for Vedolizumab Treatment in Crohn's Disease: A Multicenter Retrospective Study.Gastroenterology report · 2025Article
- [Application of advanced treatment in chronic inflammatory bowel diseases].Innere Medizin (Heidelberg, Germany) · 2025Review
- Ustekinumab or Vedolizumab after Failure of Anti-TNF Agents in Crohn's Disease: A Review of Comparative Effectiveness Studies.Journal of clinical medicine · 2024Review
- Leukocyte Trafficking.Gastroenterology & hepatology · 2024Article
- The Future of Advanced Therapies for Pediatric Crohn's Disease.Paediatric drugs · 2023Article
- Vedolizumab in Mild-to-Moderate Crohn's Disease Patients Naïve to Biological Therapy: A Multicentric Observational Study.Crohn's & colitis 360 · 2023Article
- Endo-histologic Normalization Is Achievable with Tofacitinib and Is Associated with Improved Clinical Outcomes.Digestive diseases and sciences · 2023Review
- Impact of artificial intelligence on prognosis, shared decision-making, and precision medicine for patients with inflammatory bowel disease: a perspective and expert opinion.Annals of medicine · 2023Review
- Precision medicine and drug optimization in adult inflammatory bowel disease patients.Therapeutic advances in gastroenterology · 2023Review
- Using a Clinical Decision Support Tool for Inflammatory Bowel Disease.Gastroenterology & hepatology · 2022Article
- Role of integrin expression in the prediction of response to vedolizumab: A prospective real-life multicentre cohort study.Clinical and translational medicine · 2022Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Erratum issuedCorrigendum.2021
Authors and funding
26 authors at 18 institutions in 4 countries.
Funding
Abstract
backgroundA clinical decision support tool (CDST) has been validated for predicting treatment effectiveness of vedolizumab (VDZ) in Crohn's disease.
aimTo assess the utility of this CDST for predicting exposure-efficacy and disease outcomes.
methodsUsing data from three independent datasets (GEMINI, GETAID and VICTORY), we assessed clinical remission rates and measured VDZ exposure, rapidity of onset of action, response to dose optimisation and progression to surgery by CDST-defined response groups (low, intermediate and high).
resultsA linear relationship existed between CDST-defined groups, measured VDZ exposure, rapidity of onset of action and efficacy in GEMINI through week 52 (P < 0.001 at all time points across three CDST-defined groups). In GETAID, CDST predicted differences in clinical remission at week 14 (AUC = 0.68) and rapidity of onset of action (P = 0.04) between probability groups. The high-probability patients did not benefit from shortening of infusion intervals, and differences in onset of action between the high-intermediate and low-probability groups within GETAID were no longer significant when including low-probability patients who received a week 10 infusion. CDST predicted a twofold increase in surgery risk over 12 months of VDZ therapy among low- to intermediate-probability vs high-probability patients (adjusted HR 2.06, 95% CI 1.33-3.21).
conclusionsWe further extended the clinical utility of a previously validated VDZ CDST, which accurately predicts at baseline exposure-efficacy relationships and rapidity of onset of action and could be used to help identify patients who would most benefit from interval shortening and those most likely to require surgery while on active therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.